APMDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Apnimed, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Sep 8, 2026
$16.59−1.17 (-6.56%)
Close on Oct 19, 2026
- Market cap
- $536.90M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Sep 8, 2026 | During market hours | $12.08M | $3.91 | – |
Press releases
Announcements Apnimed filed with the SEC
Apnimed Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K